Drostanolone enanthate 200 mg/mL

Basic Info

CAS Number	13425-31-5
Active Ingredient	Drostanolone (2α-methyl-dihydrotestosterone derivative), as enanthate or propionate
Dosage Form	Oil vial
Specification & Packaging	Strength: 200 mg/mL Pack: 1 × 10 mL vial Group: 02 Item No.: 20

Storage & Common Excipients

Storage Conditions	Tightly closed, protected from light, 15–25 °C; follow the product label
Common Excipients	Typical oil formulation: castor or peanut oil, polysorbate 80, benzyl alcohol, benzyl benzoate, edetate disodium; confirm against COA

Product Introduction

An androgenic drug with anti-androgenic and weak anabolic activity. An oral formulation (drostanolone tablets) is used for benign prostatic hyperplasia and androgenic alopecia; the entries here are compounded oil-based ester injectables.

Therapeutic Use

Benign prostatic hyperplasia, male-pattern androgenic alopecia, acne; use in women requires great caution. The injectable ester forms have no approved indication in most markets

Mode of Action

5α-reductase-inhibitor-like structure with dual antagonist/partial-agonist activity at the androgen receptor; anti-androgenic effect dominates the anabolic one; not significantly aromatised; preferential action in DHT-target tissues

Administration & Monitoring

Use as prescribed; with long-term use monitor PSA, lipids, liver function, and menstrual/endocrine changes in women

Important Safety Information

Prescription medicine; non-medical abuse is unlawful. Combining with other anabolic steroids may aggravate androgenic adverse effects

Adverse Reactions

Injection-site reactions; headache, flushing; raised PSA and prostatic irritation in men; menstrual disturbance, hirsutism and voice change in women; mild transaminase elevation and lipid changes with long-term use

Important Risks

Fluctuating testosterone levels if doses are missed; low but non-zero gynaecomastia risk; adverse lipid profile

Contraindications

Hypersensitivity; pregnancy and lactation; known or suspected prostate or breast cancer; urinary obstruction in men; paediatric use

Special Populations

Contraindicated in children and adolescents; assess the prostate in older males; generally avoided in women of childbearing potential unless benefits clearly outweigh risks

Usage Limitations

Prescription-only; availability of the injectable form depends on local regulation; periodic review required for long-term therapy

Anti-Doping Testing

Drostanolone is on the WADA Prohibited List S1.1; urinary targets are drostanolone and its metabolites, detected by GC-MS/MS and LC-MS/MS

Product Quality Testing

Identification (HPLC/MS/FTIR), assay and content uniformity, related substances, clarity and particulate matter, fill volume, sterility and endotoxin, residual solvents, stability; COA